Key takeaways for Wyoming
- • No GLP-1 is FDA-approved for metabolic syndrome itself.
- • Treat via component diagnoses: obesity, T2D, CV risk, hypertension.
- • All 5 NCEP criteria typically improve on GLP-1 therapy.
- • Wyoming Medicaid coverage rules apply for Metabolic Syndrome patients in Wyoming — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Metabolic Syndrome
No GLP-1 is FDA-approved for metabolic syndrome as a discrete diagnosis. Coverage and treatment typically flow through component diagnoses (obesity, T2D, CVD risk). Evidence grade: B (consistent benefit across component endpoints). GLP-1 therapy reliably improves all five NCEP-ATP III metabolic syndrome criteria: waist circumference, triglycerides, HDL, blood pressure, and fasting glucose. STEP 1 secondary analyses showed roughly 50% of subjects met metabolic syndrome criteria at baseline and a substantial fraction resolved on treatment.
Wyoming-specific context
Wyoming has telehealth access concentrated in Cheyenne, Casper, Laramie metros, with additional reach to Gillette and Rock Springs. Wyoming Medical Center, Cheyenne Regional Medical Center is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.wyo.gov.
Wyomingtelehealth & pricing rules
- • Wyoming permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Wyoming allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Wyoming: ~$251/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.